{"id":1063343,"date":"2012-09-09T15:52:26","date_gmt":"2012-09-09T15:52:26","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/stemcells-inc-hails-40-million-in-awards-from-california-stem-cell-agency\/"},"modified":"2024-08-17T20:28:52","modified_gmt":"2024-08-18T00:28:52","slug":"stemcells-inc-hails-40-million-in-awards-from-california-stem-cell-agency-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/stemcells-inc-hails-40-million-in-awards-from-california-stem-cell-agency-2.php","title":{"rendered":"StemCells, Inc., Hails $40 Million in Awards from California Stem Cell Agency"},"content":{"rendered":"<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/yRpm_vIeMP3GtWQCxS9xYiLViS8\/0\/da\"><img decoding=\"async\" src=\"http:\/\/www.longevitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/77c88_di\" border=\"0\" style=\"padding-left:10px; padding-right: 10px;\"><\/a><br><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/yRpm_vIeMP3GtWQCxS9xYiLViS8\/1\/da\"><img decoding=\"async\" src=\"http:\/\/www.longevitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/77c88_di\" border=\"0\" style=\"padding-left:10px; padding-right: 10px;\"><\/a><\/p><p><b>StemCells, Inc<\/b>., was quick this morning<br>with a press release about <a href=\"http:\/\/californiastemcellreport.blogspot.com\/2012\/09\/stemcells-inc-wins-another-20-million.html\">winning a $20 million award<\/a> last night from the<br>California stem cell agency.<\/p><div><\/div><div>The publicly traded, Newark, Ca., firm<br>also pointed out that the <b>CIRM<\/b> board in July awarded another $20<br>million to the business.<\/div><div><\/div><div><a href=\"http:\/\/investor.stemcellsinc.com\/phoenix.zhtml?c=86230&amp;p=irol-newsArticle&amp;ID=1732291&amp;highlight=\">The news release<\/a> hailed the awards as<br>validating its science and business. <b>Martin McGlynn<\/b>, who personally<br>appeared before the CIRM board last night, said,<\/div><blockquote><p>&nbsp;\"CIRM's approval of two<br>awards to&nbsp;StemCells&nbsp;illustrates the tremendous promise of<br>our neural stem cell technology and the high degree of confidence in<br>the world class team of scientists and clinicians who will be working<br>to translate this technology into potential treatments and cures for<br>these devastating diseases.\"&nbsp;<\/p><\/blockquote><div>On the Alzheimer's award last night,<br>McGlynn said,<\/div><blockquote><p>&nbsp;\"With the recent spate of late-stage clinical<br>failures in Alzheimer's disease, it is clear that the field could<br>benefit from alternative approaches to lessen the huge burden on<br>families, caregivers and our healthcare system.<\/p><\/blockquote><div>He continued,<\/div><blockquote><p>\"Our recently reported preclinical<br>data, which showed that our neural stem cells restored memory and<br>enhanced synaptic function in two animal models relevant to<br>Alzheimer's disease, shows our approach has promise.&nbsp;We greatly<br>appreciate the support from CIRM, which should help us accelerate our<br>efforts to test our HuCNS-SC cells in Alzheimer's disease.\"<\/p><\/blockquote><div>The news release did not note that the<br>board has required that the firm must show proof that it has access<br>to $20 million in matching funds prior to receiving cash from the<br>agency on the Alzheimer's grant. The <b>California Stem Cell Repor<\/b>t is<br>asking CIRM whether that requirement extends to the earlier grant as<br>well.<\/div><div><\/div><div>One of the analysts who follows the<br>company released <a href=\"http:\/\/lifetechcapital.com\/ltc\/wp-content\/uploads\/2012\/09\/Morning-Note-09-06-12-STEM.pdf\">a special report<\/a> on the firm this morning. <b>Stephen<br>Dunn <\/b>of <b>LifeTech Capital<\/b> said,<\/div><blockquote><p>&nbsp;&ldquo;We are reiterating our strong<br>speculative buy with a price target of $4.50 as StemCells Inc.<br>continues to distinguishing themselves as one of the most advanced<br>players in the stem cell space.&rdquo;<\/p><\/blockquote><div>At the time of this writing, the firm's<br>stock was trading at $2.20 up seven cents. Its 52 week high is $2.67<br>and its 52 week low is 59 cents. &nbsp;<\/div><div><img loading=\"lazy\" decoding=\"async\" width=\"1\" height=\"1\" src=\"http:\/\/www.longevitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/77c88_10000891-6622139862386203789?l=californiastemcellreport.blogspot.com\" alt=\"\" style=\"padding-left:10px; padding-right: 10px;\"><\/div><p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.longevitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/b7b1e_U-8L77cCPpU\" height=\"1\" width=\"1\" style=\"padding-left:10px; padding-right: 10px;\">Source:<br><a href=\"http:\/\/californiastemcellreport.blogspot.com\/feeds\/posts\/default?alt=rss\">http:\/\/californiastemcellreport.blogspot.com\/feeds\/posts\/default?alt=rss<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>StemCells, Inc., was quick this morningwith a press release about winning a $20 million award last night from theCalifornia stem cell agency.The publicly traded, Newark, Ca., firmalso pointed out that the CIRM board in July awarded another $20million to the &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/stemcells-inc-hails-40-million-in-awards-from-california-stem-cell-agency-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063343","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063343"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063343"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063343\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}